Annexin A2 system in human biology: Cell surface and beyond

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 4, 2013, Pages 338-346

  Luo, Min ^a   Hajjar, Katherine A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

annexin A2; fibrinolysis; inflammation; S100A2 protein p11

Indexed keywords

ANNEXIN A2 ANTIBODY; INFLAMMASOME; LIPOCORTIN 2; OXYGEN; PLASMIN; PROTEIN; PROTEIN ANTIBODY; PROTEIN S100A10; SEROTONIN RECEPTOR; SODIUM CHANNEL; TAU PROTEIN; TETRAMER; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; ARTICLE; ASEPTIC ARTHRITIS; BLEEDING; BLOOD VESSEL OCCLUSION; BRAIN CORTEX; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL GROWTH; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CYTOKINE RELEASE; CYTOLOGY; CYTOPLASM; DENDRITIC CELL; DYNAMICS; ENDOSOME; FIBRINOLYSIS; FRONTOTEMPORAL DEMENTIA; GLIOBLASTOMA; HUMAN; HYPERFIBRINOLYSIS; HYPOXIA; LYSOSOME; MICROTUBULE; MULTIPLE MYELOMA; NERVE CELL; NOCICEPTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PLASMA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RETINA; RETINA NEOVASCULARIZATION; SOLID TUMOR; THROMBOSIS; TUMOR INVASION;

ANIMALS; ANNEXIN A2; CELL MEMBRANE; FIBRINOLYSIS; HUMANS; S100 PROTEINS;

EID: 84878306011     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1334143     Document Type: Article

References (129)

1. Moss S. E., Morgan R. O. The annexins. Genome Biol: 2004; 5 1 8
2. Rand J. H. "Annexinopathieso"-a new class of diseases. N Engl J Med: 1999; 340 13 1035 1036
3. Rand J. H. The annexinopathies: a new category of diseases. Biochim Biophys Acta: 2000; 1498 2-3 169 173
4. Hayes M. J., Moss S. E. Annexins and disease. Biochem Biophys Res Commun: 2004; 322 4 1166 1170 (Pubitemid 39164646)
5. Hayes M. J., Longbottom R. E., Evans M. A., Moss S. E. Annexinopathies. Subcell Biochem: 2007; 45 1 28
6. Fatimathas L., Moss S. E. Annexins as disease modifiers. Histol Histopathol: 2010; 25 4 527 532
7. Heizmann C. W., Ackermann G. E., Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem: 2007; 45 93 138
8. Hedhli N., Falcone D. J., Huang B., et al. The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol: 2012; 2012 406273
9. Gerke V., Creutz C. E., Moss S. E. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol: 2005; 6 6 449 461 (Pubitemid 40780557)
10. Gerke V., Moss S. E. Annexins: from structure to function. Physiol Rev: 2002; 82 2 331 371 (Pubitemid 34654456)
11. Spano F., Raugei G., Palla E., Colella C., Melli M. Characterization of the human lipocortin-2-encoding multigene family: its structure suggests the existence of a short amino acid unit undergoing duplication. Gene: 1990; 95 2 243 251
12. Waisman D. M. Annexin II tetramer: structure and function. Mol Cell Biochem: 1995; 149-150 301 322
13. Rescher U., Gerke V. S100A10/p11: Family, friends, and functions. Pflugers Arch Eur J Physiol: 2007; 455 575 582
14. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol: 2001; 33 7 637 668 (Pubitemid 32520962)
15. Réty S., Sopkova J., Renouard M., et al. The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nat Struct Biol: 1999; 6 1 89 95 (Pubitemid 29232429)
16. Knop M., Aareskjold E., Bode G., Gerke V. Rab3D and annexin A2 play a role in regulated secretion of vWF, but not tPA, from endothelial cells. EMBO J: 2004; 23 15 2982 2992 (Pubitemid 39093592)
17. Umbrecht-Jenck E., Demais V., Calco V., Bailly Y., Bader M. F., Chasserot-Golaz S. S100A10-mediated translocation of annexin-A2 to SNARE proteins in adrenergic chromaffin cells undergoing exocytosis. Traffic: 2010; 11 7 958 971
18. Wang P., Chintagari N. R., Gou D., Su L., Liu L. Physical and functional interactions of SNAP-23 with annexin A2. Am J Respir Cell Mol Biol: 2007; 37 4 467 476 (Pubitemid 47502722)
19. Zobiack N., Rescher U., Ludwig C., Zeuschner D., Gerke V. The annexin 2/S100A10 complex controls the distribution of transferrin receptor-containing recycling endosomes. Mol Biol Cell: 2003; 14 12 4896 4908 (Pubitemid 37484805)
20. Eberhard D. A., Karns L. R., VandenBerg S. R., Creutz C. E. Control of the nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 binding. J Cell Sci: 2001; 114 Pt 17 3155 3166 (Pubitemid 32910470)
21. Vedeler A., Hollås H., Grindheim A. K., Raddum A. M. Multiple roles of annexin A2 in post-transcriptional regulation of gene expression. Curr Protein Pept Sci: 2012; 13 4 401 412
22. Grieve A. G., Moss S. E., Hayes M. J. Annexin A2 at the interface of actin and membrane dynamics: a focus on its roles in endocytosis and cell polarization. Int J Cell Biol: 2012; 2012 852430
23. Flood E. C., Hajjar K. A. The annexin A2 system and vascular homeostasis. Vascul Pharmacol: 2011; 54 3-6 59 67
24. Dassah M., Deora A. B., He K., Hajjar K. A. The endothelial cell annexin A2 system and vascular fibrinolysis. Gen Physiol Biophys: 2009; 28 Spec No Focus F20 F28
25. Madureira P. A., Surette A. P., Phipps K. D., Taboski M. AS, Miller V. A., Waisman D. M. The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood: 2011; 118 18 4789 4797
26. Cesarman-Maus G., Hajjar K. A. Molecular mechanisms of fibrinolysis. Br J Haematol: 2005; 129 3 307 321 (Pubitemid 40646889)
27. Hajjar K. A. The molecular basis of fibrinolysis. In: Orkin S. H., Nathan D. G., Ginsburg D., Look A. T., Fisher D. E., Lux S. E., eds. Nathan and Oski's Hematology of Infancy and Childhood. 7th ed. Philadelphia Saunders Elsevier: 2009; 1425 1447
28. Hajjar K. A., Ruan J. Fibrinolysis and thrombolysis. In: Kaushansky K., Lichtman M. A., Beutler E., Kipps T. J., Seligsohn U., Prchal J. T., eds. Williams Hematology. 8th ed. New York McGraw-Hill: 2010; 2219 2246
29. Valapala M., Vishwanatha J. K. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem: 2011; 286 35 30911 30925
30. Faure A. V., Migné C., Devilliers G., Ayala-Sanmartin J. Annexin 2 "secretiono" accompanying exocytosis of chromaffin cells: possible mechanisms of annexin release. Exp Cell Res: 2002; 276 1 79 89 (Pubitemid 34948353)
31. Danielsen E. M., van Deurs B., Hansen G. H. "Nonclassicalo" secretion of annexin A2 to the lumenal side of the enterocyte brush border membrane. Biochemistry: 2003; 42 49 14670 14676 (Pubitemid 37532014)
32. Keller M., Rüegg A., Werner S., Beer H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell: 2008; 132 5 818 831 (Pubitemid 351312798)
33. Peterson E. A., Sutherland M. R., Nesheim M. E., Pryzdial E. L. Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2. J Cell Sci: 2003; 116 Pt 12 2399 2408 (Pubitemid 36790122)
34. Deora A. B., Kreitzer G., Jacovina A. T., Hajjar K. A. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem: 2004; 279 42 43411 43418 (Pubitemid 39390640)
35. Huang B., Deora A. B., He K. L., et al. Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice. Blood: 2011; 118 10 2918 2929
36. Erikson E., Erikson R. L. Identification of a cellular protein substrate phosphorylated by the avian sarcoma virus-transforming gene product. Cell: 1980; 21 3 829 836 (Pubitemid 10022891)
37. He K. L., Deora A. B., Xiong H., et al. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. J Biol Chem: 2008; 283 28 19192 19200
38. He K. L., Sui G., Xiong H., et al. Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2. J Biol Chem: 2011; 286 17 15428 15439
39. Jost M., Gerke V. Mapping of a regulatory important site for protein kinase C phosphorylation in the N-terminal domain of annexin II. Biochim Biophys Acta: 1996; 1313 3 283 289 (Pubitemid 26342960)
40. Hajjar K. A., Jacovina A. T., Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem: 1994; 269 33 21191 21197
41. Cesarman G. M., Guevara C. A., Hajjar K. A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem: 1994; 269 33 21198 21203
42. O'Connell P. A., Surette A. P., Liwski R. S., Svenningsson P., Waisman D. M. S100A10 regulates plasminogen-dependent macrophage invasion. Blood: 2010; 116 7 1136 1146
43. Das R., Burke T., Plow E. F. Histone H2B as a functionally important plasminogen receptor on macrophages. Blood: 2007; 110 10 3763 3772 (Pubitemid 350159647)
44. Hajjar K. A., Mauri L., Jacovina A. T., et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem: 1998; 273 16 9987 9993 (Pubitemid 28183100)
45. Hajjar K. A., Guevara C. A., Lev E., Dowling K., Chacko J. Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. Essential role of endonexin repeat 2. J Biol Chem: 1996; 271 35 21652 21659 (Pubitemid 26293036)
46. Ling Q., Jacovina A. T., Deora A. B., et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest: 2004; 113 1 38 48 (Pubitemid 38541630)
47. Surette A. P., Madureira P. A., Phipps K. D., Miller V. A., Svenningsson P., Waisman D. M. Regulation of fibrinolysis by S100A10 in vivo. Blood: 2011; 118 11 3172 3181
48. Jacovina A. T., Deora A. B., Ling Q., et al. Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest: 2009; 119 11 3384 3394
49. Selhub J. Homocysteine metabolism. Annu Rev Nutr: 1999; 19 217 246 (Pubitemid 29380603)
50. Humphrey L. L., Fu R., Rogers K., Freeman M., Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc: 2008; 83 11 1203 1212
51. Bonaa K. H., Njolstad I., Ueland P. M., et al. NORVIT Trial Investigators Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med: 2006; 354 15 1578 1588
52. Hajjar K. A. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest: 1993; 91 6 2873 2879 (Pubitemid 23182548)
53. Markus H. S. Genes, endothelial function and cerebral small vessel disease in man. Exp Physiol: 2008; 93 1 121 127 (Pubitemid 350293974)
54. Wong A., Mok V., Fan Y. H., Lam W. WM, Liang K. S., Wong K. S. Hyperhomocysteinemia is associated with volumetric white matter change in patients with small vessel disease. J Neurol: 2006; 253 4 441 447 (Pubitemid 43965608)
55. Zhu H., Fan X., Yu Z., et al. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab: 2010; 30 6 1137 1146
56. Tanaka Y., Ishii H., Hiraoka M., et al. Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: a magnetic resonance imaging study. Brain Res: 2007; 1165 135 143 (Pubitemid 47210968)
57. Walvick R. P., Bråtane B. T., Henninger N., et al. Visualization of clot lysis in a rat embolic stroke model: application to comparative lytic efficacy. Stroke: 2011; 42 4 1110 1115
58. Ishii H., Yoshida M., Hiraoka M., et al. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res: 2001; 89 12 1240 1245 (Pubitemid 34627884)
59. Fan X., Yu Z., Liu J., et al. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. Stroke: 2010; 41 10, Suppl S54 S58
60. Yepes M., Sandkvist M., Moore E. G., Bugge T. H., Strickland D. K., Lawrence D. A. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest: 2003; 112 10 1533 1540 (Pubitemid 38056279)
61. Wang X., Tsuji K., Lee S. R., et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke: 2004; 35 11 01 2726 2730 (Pubitemid 39458380)
62. Kaur J., Zhao Z., Klein G. M., Lo E. H., Buchan A. M. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab: 2004; 24 9 945 963
63. Cockrell E., Espinola R. G., McCrae K. R. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus: 2008; 17 10 943 951
64. Cohen D., Berger S. P., Steup-Beekman G. M., Bloemenkamp K. WM, Bajema I. M. Diagnosis and management of the antiphosphlipid syndrome. BMJ: 2010; 340 1125 1132
65. Cesarman-Maus G., Ríos-Luna N. P., Deora A. B., et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood: 2006; 107 11 4375 4382 (Pubitemid 43801363)
66. Ao W., Zheng H., Chen X. W., Shen Y., Yang C. D. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int: 2011; 31 7 865 869
67. Cesarman-Maus G., Cantú-Brito C., Barinagarrementeria F., et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke: 2011; 42 2 501 503
68. Salle V., Mazière J. C., Brulé A., et al. Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome. Eur J Intern Med: 2012; 23 7 665 668
69. Salle V., Mazière J. C., Smail A., et al. Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome. J Clin Immunol: 2008; 28 4 291 297
70. Ao W., Zheng H., Chen X. W., Shen Y., Yang C. D. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int: 2011; 31 7 865 869
71. Yung S., Cheung K. F., Zhang Q. Y., Chan T. M. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol: 2010; 21 11 1912 1927
72. Krone K. A., Allen K. L., McCrae K. R. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep: 2010; 12 1 53 57
73. Platt O. S. Preventing stroke in sickle cell anemia. N Engl J Med: 2005; 353 26 2743 2745 (Pubitemid 43016813)
74. Sebastiani P., Ramoni M. F., Nolan V., Baldwin C. T., Steinberg M. H. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet: 2005; 37 4 435 440
75. Flanagan J. M., Frohlich D. M., Howard T. A., et al. Genetic predictors for stroke in children with sickle cell anemia. Blood: 2011; 117 24 6681 6684
76. Baldwin C. T., Nolan V. G., Wyszynski D. F., et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood: 2005; 106 1 372 375 (Pubitemid 40967216)
77. Ashley-Koch A. E., Elliott L., Kail M. E., et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood: 2008; 111 12 5721 5726
78. Stein E., McMahon B., Kwaan H., Altman J. K., Frankfurt O., Tallman M. S. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol: 2009; 22 1 153 163
79. Menell J. S., Cesarman G. M., Jacovina A. T., McLaughlin M. A., Lev E. A., Hajjar K. A. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med: 1999; 340 13 994 1004 (Pubitemid 29157631)
80. Liu Y., Wang Z., Jiang M., et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res: 2011; 35 7 879 884
81. O'Connell P. A., Madureira P. A., Berman J. N., Liwski R. S., Waisman D. M. Regulation of S100A10 by the PML-RAR-α oncoprotein. Blood: 2011; 117 15 4095 4105
82. Jácomo R. H., Santana-Lemos B. A., Lima A. SG., et al. Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. Blood: 2012; 120 1 207 213
83. Smith L. E., Wesolowski E., McLellan A., et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci: 1994; 35 1 101 111 (Pubitemid 24046832)
84. Valapala M., Thamake S. I., Vishwanatha J. K. A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci: 2011; 124 Pt 9 1453 1464
85. Zhao S., Huang L., Wu J., Zhang Y., Pan D., Liu X. Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy. Mol Vis: 2009; 15 1231 1242
86. Sato T., Kusaka S., Hashida N., Saishin Y., Fujikado T., Tano Y. Comprehensive gene-expression profile in murine oxygen-induced retinopathy. Br J Ophthalmol: 2009; 93 1 96 103
87. Zhao S. H., Pan D. Y., Zhang Y., Wu J. H., Liu X., Xu Y. Annexin A2 promotes choroidal neovascularization by increasing vascular endothelial growth factor expression in a rat model of argon laser coagulation-induced choroidal neovascularization. Chin Med J (Engl): 2010; 123 6 713 721
88. Lima e Silva R., Shen J., Gong Y. Y., et al. Agents that bind annexin A2 suppress ocular neovascularization. J Cell Physiol: 2010; 225 3 855 864
89. Rao J. S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer: 2003; 3 7 489 501 (Pubitemid 37328837)
90. Tsatas D., Kaye A. H. The role of the plasminogen activation cascade in glioma cell invasion: a review. J Clin Neurosci: 2003; 10 2 139 145 (Pubitemid 36358356)
91. Maruo T., Ichikawa T., Kanzaki H., et al. Proteomics-based analysis of invasion-related proteins in malignant gliomas. Neuropathology: 2012;; Epub ahead of print
92. Beckner M. E., Chen X., An J., Day B. W., Pollack I. F. Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest: 2005; 85 3 316 327 (Pubitemid 40333149)
93. Zhai H., Acharya S., Gravanis I., et al. Annexin A2 promotes tumor progression in glioma cells. J Neurosci: 2011; 31 40 14346 14360
94. Reeves S. A., Chavez-Kappel C., Davis R., Rosenblum M., Israel M. A. Developmental regulation of annexin II (lipocortin 2) in human brain and expression in high grade glioma. Cancer Res: 1992; 52 24 6871 6876 (Pubitemid 23006292)
95. Nygaard S. J., Haugland H. K., Kristoffersen E. K., Lund-Johansen M., Laerum O. D., Tysnes O. B. Expression of annexin II in glioma cell lines and in brain tumor biopsies. J Neurooncol: 1998; 38 1 11 18 (Pubitemid 28107888)
96. Roseman B. J., Bollen A., Hsu J., Lamborn K., Israel M. A. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res: 1994; 6 12 561 567
97. Sharma M., Blackman M. R., Sharma M. C. Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol: 2012; 92 1 175 184
98. Sharma M. R., Koltowski L., Ownbey R. T., Tuszynski G. P., Sharma M. C. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol: 2006; 81 2 146 156 (Pubitemid 44715786)
99. Sharma M., Ownbey R. T., Sharma M. C. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol: 2010; 88 2 278 286
100. Phipps K. D., Surette A. P., O'Connell P. A., Waisman D. M. Plasmingen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res: 2011; 7 6676 6683
101. Swisher J. FA, Burton N., Bacot S. M., Vogel S. N., Feldman G. M. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood: 2010; 115 3 549 558
102. Seckinger A., Meissner T., Moreaux J., et al. Clinical and prognostic role of annexin A2 in multiple myleoma. Blood: 2012; 120 10871094
103. Claudio J. O., Masih-Khan E., Tang H., et al. A molecular compendium of genes expressed in multiple myeloma. Blood: 2002; 100 6 2175 2186 (Pubitemid 35001254)
104. Bao H., Jiang M., Zhu M., Sheng F., Ruan J., Ruan C. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol: 2009; 90 2 177 185
105. D'Souza S., Kurihara N., Shiozawa Y., et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood: 2012; 119 8 1888 1896
106. Shiozawa Y., Havens A. M., Jung Y., et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem: 2008; 105 2 370 380
107. Svenningsson P., Greengard P. p11 (S100A10)-an inducible adaptor protein that modulates neuronal functions. Curr Opin Pharmacol: 2007; 7 1 27 32
108. Svenningsson P., Chergui K., Rachleff I., et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science: 2006; 311 5757 77 80 (Pubitemid 43063061)
109. Alexander B., Warner-Schmidt J. L., Eriksson T., et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med: 2010; 2 54 54ra76
110. Zhang L., Su T. P., Choi K., et al. P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. J Psychiatr Res: 2011; 45 4 435 441
111. Huang X. L., Pawliczak R., Yao X. L., et al. Interferon-gamma induces p11 gene and protein expression in human epithelial cells through interferon-gamma-activated sequences in the p11 promoter. J Biol Chem: 2003; 278 11 9298 9308 (Pubitemid 36800414)
112. Warner-Schmidt J. L., Vanover K. E., Chen E. Y., Marshall J. J., Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA: 2011; 108 22 9262 9267
113. Chen G., Twyman R., Manji H. K. p11 and gene therapy for severe psychiatric disorders: a practical goal? Sci Transl Med: 2010; 2 54 54ps51
114. Okuse K., Malik-Hall M., Baker M. D., et al. Annexin II light chain regulates sensory neuron-specific sodium channel expression. Nature: 2002; 417 6889 653 656 (Pubitemid 34614824)
115. Rezvanpour A., Shaw G. S. Unique S100 target protein interactions. Gen Physiol Biophys: 2009; 28 Spec No Focus F39 F46
116. Foulkes T., Nassar M. A., Lane T., et al. Deletion of annexin 2 light chain p11 in nociceptors causes deficits in somatosensory coding and pain behavior. J Neurosci: 2006; 26 41 10499 10507 (Pubitemid 44564600)
117. Mishra M., Paunesku T., Woloschak G. E., et al. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol: 2007; 114 1 81 94 (Pubitemid 47029063)
118. Paulson H. L., Igo I. Genetics of dementia. Semin Neurol: 2011; 31 5 449 460
119. Gauthier-Kemper A., Weissmann C., Golovyashkina N., et al. The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J Cell Biol: 2011; 192 4 647 661
120. Bashir R., Britton S., Strachan T., et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet: 1998; 20 1 37 42 (Pubitemid 28410340)
121. Liu J., Aoki M., Illa I., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet: 1998; 20 1 31 36 (Pubitemid 28410339)
122. Campanaro S., Romualdi C., Fanin M., et al. Gene expression profiling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet: 2002; 11 26 3283 3298 (Pubitemid 36054657)
123. Cagliani R., Magri F., Toscano A., et al. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat: 2005; 26 3 283
124. Lennon N. J., Kho A., Bacskai B. J., Perlmutter S. L., Hyman B. T., Brown R. H. Jr. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem: 2003; 278 50 50466 50473 (Pubitemid 37548892)
125. Cobelli N., Scharf B., Crisi G. M., Hardin J., Santambrogio L. Mediators of the inflammatory response to joint replacement devices. Nat Rev Rheumatol: 2011; 7 10 600 608
126. Maitra R., Clement C. C., Scharf B., et al. Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis. Mol Immunol: 2009; 47 2-3 175 184
127. Scharf B., Clement C. C., Wu X. X., et al. Annexin A2 binds to endosomes following organelle destabilization by particulate wear debris. Nat Commun: 2012; 3 755 765
128. Kassam G., Choi K. S., Ghuman J., et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem: 1998; 273 8 4790 4799 (Pubitemid 28103230)
129. Kassam G., Le B. H., Choi K. S., et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry: 1998; 37 16958 16966 (Pubitemid 28566773)